Revvity Announces An Expansion Of Its Work With Genomics England That Leverages Both Organizations' Expertise And Resources To Advance Critical Genomic Initiatives Across The United Kingdom
Revvity Announces An Expansion Of Its Work With Genomics England That Leverages Both Organizations' Expertise And Resources To Advance Critical Genomic Initiatives Across The United Kingdom
Revvity, Inc. (NYSE:RVTY), today announced an expansion of its work with Genomics England that leverages both organizations' expertise and resources to advance critical genomic initiatives across the United Kingdom. Building on the parties' long and productive work history, this advanced collaboration is dedicated to accelerating Genomics England's renowned research programs, supporting diverse areas in genomics, and fostering talent in innovative healthcare fields.
Revvity, Inc.（紐交所：RVTY）今天宣佈擴大與Genomics England的合作範圍，藉助雙方的專業知識和資源推動英國各地關鍵基因組倡議的發展。在雙方長期而富有成效的合作基礎上，這一前沿合作旨在加速Genomics England著名的研究項目，支持基因組學領域的多個方面，並促進創新醫療領域的人才培養。
A cornerstone of the collaboration is the Generation Study, a world-leading study led by Genomics England, in partnership with the National Health Service, that aims to screen up to 100,000 newborns for 200 rare genetic conditions in England. In the study, which launched earlier this year, Revvity's Omics laboratory in Manchester, UK will work with Genomics England to advance the early detection of genetic conditions in newborns. Utilizing the chemagic 360 instrument, Revvity's team will extract DNA from cord blood samples collected from newborns across England.
合作的核心是「Generation Study」，這是由Genomics England領導的世界領先研究，與英國國家醫療服務體系合作，旨在對英國的多達10萬名新生兒進行檢測，以篩選出200種罕見遺傳病。在今年早些時候啓動的研究中，Revvity的Omics實驗室將與Genomics England合作，在曼徹斯特的工作中，推動新生兒遺傳病的早期檢測。利用chemagic 360儀器，Revvity的團隊將從英格蘭各地收集的新生兒臍帶血樣本中提取DNA。
譯文內容由第三人軟體翻譯。
